Background: Cancer patients with venous thromboembolism (VTE) have an increased incidence of bleeding complications while on anticoagulant therapy. Methods: RIETE is an ongoing registry of consecutive patients with acute VTE. We tried to identify which cancer patients are at a higher risk for major bleeding. Results: Up to May 2009, 4,709 patients with active cancer had been enrolled in RIETE registry. During the first 3 months of anticoagulant therapy, 200 (4.2%) patients developed major bleeding. Then, 38 (0.8%) further patients bled beyond the first 90 days of therapy, 3 bled after withholding anticoagulant therapy. The most common sites of bleeding were the gastrointestinal tract (118 patients, 49%), genitourinary system (43 patients, 18%) and the brain (27 patients, 11%). In all, 160 patients (66%) died within 30 days after bleeding: 88 (55%) died of bleeding, 3 (1.9%) died of recurrent pulmonary embolism. Conclusions: Major bleeding is a frequent and severe complication in cancer patients with VTE, even beyond the third month. One third of the patients who bled died due the bleeding event.

Bleeding complications associated with anticoagulant therapy in patients with cancer / Trujillo-Santos, J., Nieto, J.A., Ruiz-Gamietea, A., Lopez-Jimenez, L., Garcia-Bragado, F., Quintavalla, R., Monreal, M., Pasca, S.. - In: THROMBOSIS RESEARCH. - ISSN 0049-3848. - 125:(2010), pp. S58-S61. [10.1016/S0049-3848(10)70015-3]

Bleeding complications associated with anticoagulant therapy in patients with cancer

Pasca S
2010-01-01

Abstract

Background: Cancer patients with venous thromboembolism (VTE) have an increased incidence of bleeding complications while on anticoagulant therapy. Methods: RIETE is an ongoing registry of consecutive patients with acute VTE. We tried to identify which cancer patients are at a higher risk for major bleeding. Results: Up to May 2009, 4,709 patients with active cancer had been enrolled in RIETE registry. During the first 3 months of anticoagulant therapy, 200 (4.2%) patients developed major bleeding. Then, 38 (0.8%) further patients bled beyond the first 90 days of therapy, 3 bled after withholding anticoagulant therapy. The most common sites of bleeding were the gastrointestinal tract (118 patients, 49%), genitourinary system (43 patients, 18%) and the brain (27 patients, 11%). In all, 160 patients (66%) died within 30 days after bleeding: 88 (55%) died of bleeding, 3 (1.9%) died of recurrent pulmonary embolism. Conclusions: Major bleeding is a frequent and severe complication in cancer patients with VTE, even beyond the third month. One third of the patients who bled died due the bleeding event.
2010
Trujillo-Santos, J.; Nieto, J. A.; Ruiz-Gamietea, A.; Lopez-Jimenez, L.; Garcia-Bragado, F.; Quintavalla, R.; Monreal, M; Pasca, S
Bleeding complications associated with anticoagulant therapy in patients with cancer / Trujillo-Santos, J., Nieto, J.A., Ruiz-Gamietea, A., Lopez-Jimenez, L., Garcia-Bragado, F., Quintavalla, R., Monreal, M., Pasca, S.. - In: THROMBOSIS RESEARCH. - ISSN 0049-3848. - 125:(2010), pp. S58-S61. [10.1016/S0049-3848(10)70015-3]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11572/500843
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 20
  • Scopus 61
  • ???jsp.display-item.citation.isi??? 54
  • OpenAlex 64
social impact